Physician
Arkansas Pain Centers, LTD
Arkansas Pain Centers, LTD was paid $1.90M by Medicaid between Jan 2018 and Nov 2024, across 71 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 41% of everything it billed.
33Billing provider infoARKANSAS PAIN CENTERS, LTD
N LITTLE ROCK, AR 72117
N LITTLE ROCK, AR 72117
33aNPI1811984099assigned 10/03/2005
33bProvider typePain Medicine Physician
28Total paid$1.90M
24GClaims267,828
24DCodes billed71
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Pain Medicine Physician providers in Arkansas
Rank by total paid#1 of 7
Median peer was paid$187K
This provider vs. median10×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 48,622 | $315K | |
| 2019 | 64,724 | $230K | |
| 2020 | 79,759 | $364K | |
| 2021 | 33,988 | $362K | |
| 2022 | 20,936 | $307K | |
| 2023 | 14,367 | $224K | |
| 2024incomplete | 5,432 | $100K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 41% | 31,106 | 22,859 | $781K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 10% | 14,836 | 10,101 | $194K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 5.9% | 15,256 | 11,219 | $112K |
| 80361 | 3.4% | 4,888 | 3,716 | $64K | |
| 80356 | 3.3% | 4,897 | 3,714 | $62K | |
| 80365 | 2.8% | 4,883 | 3,711 | $54K | |
| 80348 | 2.8% | 4,890 | 3,718 | $53K | |
| 80358 | 2.7% | 4,889 | 3,716 | $51K | |
| 80354 | 2.7% | 4,886 | 3,713 | $50K | |
| 80373 | 2.4% | 4,888 | 3,714 | $45K | |
| 80346 | 2.3% | 4,883 | 3,712 | $45K | |
| 80359 | 1.9% | 4,890 | 3,717 | $36K |
59 more codes
| 80369 | 1.8% | 4,868 | $34K | |
| 80353 | 1.7% | 4,882 | $33K | |
| 80324 | 1.7% | 4,868 | $32K | |
| 80349 | 1.6% | 4,869 | $30K | |
| 80335 | 1.3% | 4,872 | $25K | |
| 80323 | 1.2% | 4,867 | $22K | |
| 83992 | 1.2% | 4,864 | $22K | |
| 80352 | 1.2% | 4,862 | $22K | |
| 80371 | 1.1% | 4,863 | $21K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 4,658 | $17K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 1,966 | $15K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 460 | $14K |
| 80338 | <1% | 4,863 | $12K | |
| 80366 | <1% | 4,864 | $10K | |
| 80357 | <1% | 4,859 | $9K | |
| 80355 | <1% | 4,860 | $9K | |
| 98941 | Chiropractic manipulative treatment; spinal, 3-4 regions | <1% | 1,278 | $7K |
| 97032 | <1% | 1,081 | $4K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 86 | $2K |
| 97035 | <1% | 1,077 | $2K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 129 | $2K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,365 | $2K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,522 | $2K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 433 | $2K |
| 62323 | <1% | 18 | $1K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,487 | $874.98 |
| 98940 | <1% | 151 | $690.30 | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 247 | $376.15 |
| 1170F | <1% | 2,901 | $96.74 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 117 | $74.08 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | <1% | 11,510 | $56.89 |
| 97024 | <1% | 109 | $52.04 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 117 | $21.45 |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | <1% | 11,003 | $21.43 |
| G8942 | Functional outcome assessment using a standardized tool is documented within the previous 30 days and a care plan, based on identified deficiencies is documented within two days of the functional outcome assessment | <1% | 2,393 | $1.08 |
| 1006F | <1% | 8,994 | $0.67 | |
| G8756 | No documentation of blood pressure measurement, reason not given | <1% | 2,341 | $0.62 |
| G8422 | Bmi not documented, documentation the patient is not eligible for bmi calculation | <1% | 2,222 | $0.57 |
| 1036F | <1% | 5,758 | $0.45 | |
| 3288F | <1% | 1,923 | $0.31 | |
| G9561 | Patients prescribed opiates for longer than six weeks | <1% | 4,663 | $0.21 |
| G9577 | Patients prescribed opiates for longer than six weeks | <1% | 4,650 | $0.21 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 117 | $0.17 |
| G9578 | Documentation of signed opioid treatment agreement at least once during opioid therapy | <1% | 4,202 | $0.17 |
| G9562 | Patients who had a follow-up evaluation conducted at least every three months during opioid therapy | <1% | 4,188 | $0.16 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | <1% | 5,503 | $0.12 |
| G8938 | Bmi is documented as being outside of normal parameters, follow-up plan is not documented, documentation the patient is not eligible | <1% | 615 | $0.09 |
| 4004F | <1% | 4,101 | $0.09 | |
| 4040F | <1% | 3,139 | $0.06 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | <1% | 1,311 | $0.06 |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 30 | $0.05 |
| G8981 | Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 30 | $0.05 |
| 1101F | <1% | 176 | $0.01 | |
| G0030 | Patient screened for tobacco use and received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling, pharmacotherapy, or both), if identified as a tobacco user | 0% | 86 | $0.00 |
| 1007F | 0% | 13 | $0.00 | |
| 99000 | 0% | 55 | $0.00 | |
| 36416 | 0% | 89 | $0.00 | |
| G8430 | Documentation of a medical reason(s) for not documenting, updating, or reviewing the patient's current medications list (e.g., patient is in an acute health crisis where time is of the essence and delay of treatment would jeopardize the patient's health status) | 0% | 34 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 27 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGARLAPATI, BUTCHAIAH (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Arkansas Outpatient Surgery Center, LLC | North Little Rock, AR | $4K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.